Brought to you by 
Forma gives Genentech option to buy cancer candidate
21 Jan 2016
Executive Summary
Roche’s Genentech Inc. has received an exclusive global option to acquire a preclinical cancer candidate from Forma Therapeutics Inc. (addressing challenging oncology drug targets). NOTE: according to PharmaProjects, the candidate is a small-molecule nicotinamide phosphoribosyltransferase inhibitor.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Forma gives Genentech option to buy cancer candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice